It is very uncertain whether summary of findings table ‐ Rituximab changes CAS improvement (decrease) by 2 or more points compared with placebo (very low certainty).
It is very uncertain whether summary of findings table ‐ Rituximab changes NOSPECS improvement (decrease) by 2 classes or more compared with placebo (very low certainty).
Rituximab (2 x 1000 mg) plus methotrexate probably leads to higher clinical improvement American College of Rheumatology 50%… compared with methotrexate monotherapy (moderate certainty).
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in clinical remission (Disease Activity Score‐28 joint count < 2.6)… compared with methotrexate monotherapy (moderate certainty).
Rituximab (2 x 1000 mg) plus methotrexate leads to higher physical function (HAQ‐DI MCID = ‐0.22) Analysis 1.10 compared with methotrexate monotherapy (high certainty).
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in no radiographic progression in total Genant‐modified Sharp score… compared with methotrexate monotherapy (moderate certainty).
Rituximab (2 x 1000 mg) plus methotrexate leads to higher health‐related quality of life compared with methotrexate monotherapy (high certainty).
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in discontinuations due to adverse events Analysis 6.3 compared with methotrexate monotherapy (moderate certainty).
Rituximab (2 x 1000 mg) plus methotrexate showed no clear difference in serious adverse events Analysis 11.2 compared with methotrexate monotherapy (moderate certainty).
Rituximab (B cell) + steroid showed no clear difference in failure of reversal of acute rejection compared with steroid alone (moderate certainty).
Rituximab (B cell) + steroid showed no clear difference in graft loss or death with a functioning graft compared with steroid alone (moderate certainty).
Rituximab (B cell) + steroid probably leads to higher treatment adverse events: UTI/pyelonephritis compared with steroid alone (moderate certainty).
It is very uncertain whether rituximab/cyclosporin/prednisolone changes number with complete remission: complete remission in delayed… compared with cyclosporin/prednisolone (very low certainty).
It is very uncertain whether rituximab/cyclosporin/prednisolone changes number with complete remission: complete remission in all patients compared with cyclosporin/prednisolone (very low certainty).
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: bronchospasm/treatment discontinued compared with cyclosporin/prednisolone (very low certainty).
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: hypotension compared with cyclosporin/prednisolone (very low certainty).
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: skin rash compared with cyclosporin/prednisolone (very low certainty).
It is very uncertain whether rituximab/cyclosporin/prednisolone changes adverse events: mild dyspnoea compared with cyclosporin/prednisolone (very low certainty).